Spyridon Servos Email & Phone Number

Wokingham, Gb

SerGene Biosciences Ltd is a strategic advisory firm specializing in cell and gene therapy for biopharmaceutical companies. With a deep understanding of viral and non-viral delivery platforms, we provide expert guidance on business development, licensing, mergers & acquisitions, and product development.Our expertise includes:• Gene Therapy Strategy: Developing tailored gene therapy strategies aligned with therapeutic goals and regulatory requirements.• Licensing Deals: Negotiating optimal licensing agreements that protect intellectual property and maximize revenue potential.• M&A Due Diligence: Conducting comprehensive due diligence assessments to identify risks and opportunities in mergers and acquisitions.• Product Development: Optimizing nonclinical and clinical study designs to ensure efficient and effective product development.• Financial Modelling: Providing robust financial projections and risk assessments to support informed decision-making. (Xplico)• Global Network: Leveraging the advanced features of PartneringONE® to efficiently connect companies with potential partners based on specific business needs and objectives.• Business Strategy: Guide start-ups to define the best business model for commercialising their discoveries.Partner with SerGene Biosciences to leverage our expertise in gene therapy and accelerate your innovation.

Consulting Clients:Lentitek based in Edinburgh, Scotland. Lentitek has developed a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies. Get in touch if you want to learn more about evaluating and licensing their technology.SiSaf based in Guildford, England. SiSaf is a biopharmaceutical company developing RNA therapeutics that are principally focused on rare genetic disorders. Get in touch if you want to evaluate and licensing their delivery platform technology or In-House Programs. (Osteopetrosis (ADO2), Achondroplasia, Pancreatic Cancer).

Guildford, England, Gb

Oxford, Oxfordshire, Gb

Oxford, Oxfordshire, Gb

To represent the Company commercially and secure partnerships, collaborations that maximize potential revenues as well as identify and secure new opportunities to in-licence or acquire.

Oxford, Oxfordshire, Gb

Gaithersburg, Maryland, Us

Reporting to the VP of Business Development, previously to Senior Director. Responsible for coordinating all asset partnering activities of Emergent BioSciences Division and reporting to Senior and Executive Management. Achievements- Identified partner and co-managed successful sale of spiVEC™ platform- Agreed terms for commercial license with partner on a Biodefense indication- Initiated four partnering opportunities for the MVAtor™ platform (on-going) - Training in drafting commercial contracts for the pharmaceutical industry at Falconbury

Gaithersburg, Maryland, Us

Reported to the Senior Director of Business Development. Responsible for the Business Analysis function in Emergent Biosolutions BD group.Achievements- Acquisition of Zanolimumab (Financial analysis, Due diligence)- Spin-out of OETC (Financial modelling of Joint-Venture, Due Diligence, set up)- Managed UK and European BD partnering activities for the last two years of this role- Identified 5 in-licensing, 2 out-licensing and 2 M&A opportunities- Represented the company at partnering events, every year since 2006- Created an automated rNPV valuation model template for the BD group

Kidlington, Oxfordshire, Gb

Reporting to the Commercial Director. Accountable for the Business Intelligence function across the OGT Group. Achievements- Identified more than 50 companies that infringed OGT’s intellectual property. - Coordinated the development of grant proposals that secured €900,000 - Established a Knowledge Management System, which combined comprehensive market research and business intelligence.

Kidlington, Oxfordshire, Gb

Reported to the Group Managing Director. Responsible for the Budget, purchasing and CAPEX. Achievements- Co-led and delivered the operating plan for five business units. - Supported several licensing deals including a $62.5M settlement deal with Affymetrix in 2004.- Prepared Budgets (£6m) and Forecasts for five BUs of the OGT group- Supervised two BU Heads on P&L accountability.- Developed a Budgeting tool that could be updated by the BU heads and consolidate all company accounts automatically

Reported to the Commercial Director. MBA project: Evaluation of the commercialization potential and strategy targeting solid tumours markets.Achievements- Prepared sales forecasts for Scavidin, Solima and oxLDL diagnostic kit- Developed a novel commercialization algorithm for solid tumours markets- Evaluated pharmaceutical projects using real options- Organised out-licensing documentation for VEGF antagonists

Construction of Oral Vaccines, S.typhi, M.tuberculosis.

Mba (Executive Programme), Entrepreneurship, Innovation, Health Management

Ph.D., Oral Vaccines